wild-type (upper panel), sphingolipid mutants- Δsur4, Δfen1 and Δipt1 and ergosterol mutants- Δerg6, Δerg24 and Δerg4.

FIG. 35: Immunoblot of gradient fractions of Pma1p with α-PMA1 polyclonal antibody in the wild-type (upper panel), sphingolipid mutants- Δsur4, Δfen1 and Δipt1 and ergosterol mutants- Δerg6, Δerg24 and Δerg4.

LIST OF TABLES

INTRODUCTION
TABLE 1: Host defense mechanisms against Candida infection
TABLE 2: Risk factors associated with Candidiasis
TABLE 3: Species commonly causing Candidiasis and its frequency
TABLE 4: Antifungals and their mode of action
TABLE 5: Susceptibility of various Candida species
TABLE 6: Interpretive guidelines for susceptibility testing in vitro of Candida species
TABLE 7: NCCLS guidelines for antifungal susceptibility testing: M27 Document*

MATERIALS AND METHODS
TABLE 8: List of C. albicans and S. cerevisiae strains used in this study
TABLE 9: List of Plasmids used in this study
TABLE 10: Lists the primers used for PCR amplification of gene specific regions

RESULTS AND DISCUSSION
SECTION II
TABLE 11: Minimum inhibitory concentration (MIC 80μg/ml) of the host strain ADI-8u', RPCaMDRI (cells expressing the untagged wild-type CaMdr1p (without GFP)), RPCaMDRI-GFP strains, and the various mutant variants for the different drugs tested.
TABLE 12: Summarized representations of the mutant variants with drug susceptibility, drug accumulation of the two drugs: 3H-FLC and 3H-MTX and position of the variant in the motif 'C' or 'antiporter motif'.